Tag: adeno associated virus vectors in gene therapy market key players

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Grown from 2024 to 2025?#_x000D_

The market size of adeno-associated virus (AAV) vectors in gene therapy has witnessed a swift expansion recently, escalating from $2.70 billion in 2024 to $3.18 billion in 2025, representing a compound annual growth rate (CAGR) of 17.7%. This notable growth during the historic period is linked to factors like increased financial input in gene therapy studies, enhanced usage of gene modifying technologies, an upsurge in genetic anomalies and unfulfilled medical necessities, a heightened requirement for specifically targeted therapies, and increased collaborations between biotechnological businesses and research institutions._x000D_

_x000D_

#What Growth Rate Is Anticipated for the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market in the Coming Years?#_x000D_

Anticipated to experience rapid expansion in the near future, the adeno-associated virus (AVV) vectors for gene therapy market is forecasted to reach a value of $6.09 billion by 2029, with a compound annual growth rate (CAGR) of 17.6%. This growth during the forecast period can be chalked up to factors such as advancements in AAV capsid engineering, a heightened focus on precision medicine, increased funding for genetic studies and biotech, a surge in clinical trials and approvals for gene therapies, and a growing need for customised treatments. Key trends to watch out for during the forecast period involve the utilisation of artificial intelligence in AAV capsid engineering, the creation of hybrid AAV vectors that can accommodate larger genetic payloads, innovative practices in bispecific antibody-mediated AAV targeting, enhanced scalable AAV production and purification methods, and the emergence of adaptable AAV platforms that can accommodate a range of viral vectors._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp_x000D_

_x000D_

#Who Are the Leading Companies in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?#_x000D_

Major companies operating in the adeno-associated virus (AVV) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc._x000D_

_x000D_

#What Are the Key Drivers of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?#_x000D_

The surge in emphasis on gene-based therapies is anticipated to catalyze the expansion of the adeno-associated virus (AAV) vectors in the gene therapy market. These therapies attempt to amend or control genes to hinder, remediate, or eliminate diseases on a molecular scale. Progress in genetic research insights the intensified priority on establishing gene-based therapies that elevate the precision and efficacy of gene editing methods. The use of adeno-associated virus (AAV) vectors in gene therapy contributes to the formation of gene therapies by safely and effectively delivering therapeutic genes into the necessary cells, credited to their minimal immunogenicity and competency to offer sustained gene expression. For example, IQVIA, an American firm offering advanced analytical and technology solutions for the life sciences sector, reported a global expenditure of $5.9 billion on cell and gene therapies in 2023, marking a 38% rise from 2022. Therefore, the escalating emphasis on developing gene-based therapies propels the expansion of the adeno-associated virus (AAV) vectors market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp_x000D_

_x000D_

#What Are the Key Market Segments in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Industry?#_x000D_

The adeno-associated virus (AVV) vectors in gene therapy market covered in this report is segmented –_x000D_

_x000D_

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy_x000D_

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo_x000D_

3) By Scale of Operation: Preclinical, Clinical, Commercial_x000D_

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area_x000D_

_x000D_

Subsegments:_x000D_

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders_x000D_

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering_x000D_

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine_x000D_

_x000D_

#What Are the Latest Trends in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?#_x000D_

Leading firms in the adeno-associated virus (AAV) vectors within the gene therapy sector are prioritizing sophisticated innovations, such as bespoke vector diversity for assay versatility. This can enhance tissue specificity, boost therapeutic efficiency, and expedite the creation of tailored gene therapies for various conditions. Bespoke vector diversity for assay versatility implies the utilization of multiple AAV serotypes or constructs to accommodate different analytical tests and therapeutic functions. For example, in May 2024, US-based pharmaceutical entity Charles River Laboratories launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). This initiative aims to meet the expanding requirements of cell and gene therapy (CGT) development. The collection simplifies the transition from preliminary research to GMP-grade manufacturing. It contributes to standardization and enhances reliability in viral vector production. This introduction tackles a significant obstacle in elevating CGT programmes towards clinical and commercial preparedness._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report_x000D_

_x000D_

#What Are the Key Regional Markets in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Industry?#_x000D_

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the adeno-associated virus (avv) vectors in gene therapy market, and how is it changing globally?_x000D_

2. Who are the major companies in the adeno-associated virus (avv) vectors in gene therapy market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the adeno-associated virus (avv) vectors in gene therapy market right now?_x000D_

4. Which products or customer segments are growing the most in the adeno-associated virus (avv) vectors in gene therapy market?_x000D_

5. What factors are helping or slowing down the growth of the adeno-associated virus (avv) vectors in gene therapy market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Are the Key Milestones in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market’s Growth Trajectory From 2025 To 2034?

The market size for adeno-associated virus (AVV) vectors in gene therapy has seen a significant expansion in the past few years. The market is projected to balloon from $2.70 billion in 2024 to $3.18 billion in 2025, reflecting a compound annual growth rate (CAGR) of 17.7%. The exponential growth during the historical period is a result of escalated investments in gene therapy research, the surging uptake of gene editing technologies, a growing number of genetic disorders and unmet medical requirements, an increased need for targeted therapies, and an uptick in partnerships between biotech firms and research institutions.

The market size for adeno-associated virus (AVV) vectors utilized in gene therapy is predicted to undergo swift expansion in the following years, reaching a value of $6.09 billion by 2029, with a projected compound annual growth rate (CAGR) of 17.6%. The majority of this growth in the forecast period is expected to come from enhancements in AAV capsid engineering, a heightened emphasis on precision medicine, augmented financial investment in genetic research and biotechnology, an upsurge in gene therapy clinical trials and approvals, and an increased demand for personalized treatments. Key trends during the forecast period include AI advancements applied to AAV capsid engineering, the creation of hybrid AAV vectors capable of holding larger genetic payloads, the innovative approach to bispecific antibody-mediated AAV targeting, advancements in scalable AAV production and purification methodologies, and the creation of versatile AAV platforms capable of handling various viral vectors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

What Are the Core Market Drivers Propelling Growth in the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Industry?

The growth of the adeno-associated virus (AAV) vectors in the gene therapy market is anticipated to be fueled by the escalating emphasis on gene-based treatments. These treatments manipulate or modify genes to treat, prevent, or cure diseases at a molecular level. The burgeoning focus on gene-based therapies is driven by advancements in genetic research which heightens the accuracy and potency of gene editing methodologies. The utilization of adeno-associated virus (AAV) vectors in gene therapy facilitates the development of gene-based therapies by safely and efficiently introducing therapeutic genes into target cells, due to their minimal immunogenicity and capacity for long-term gene expression. For example, data from IQVIA, a US-based firm providing advanced analytics and technological solutions for the life sciences industry, showed that global expenditure on cell and gene therapies hit $5.9 billion in 2023, a 38% rise from 2022. Consequently, the growing emphasis on the development of gene-based therapies is fueling the expansion of the adeno-associated virus (AAV) vectors market.

How Is the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segmented?

The adeno-associated virus (AVV) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

Which Regions Are Driving the Next Phase of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Industry?

Prominent companies in the adeno-associated virus (AAV) vector segment of the gene therapy market are honing their focus on sophisticated innovation, including the adaptation of vector diversity for assay versatility. This is expected to augment the specificity of target tissue, enhance therapeutic effectiveness and speed up the formulation of customized gene therapies for an array of medical conditions. The modified vector diversity for assay versatility involves the use of numerous AAV serotypes or constructs, aiding a range of analytical examinations and therapeutic uses. To illustrate, Charles River Laboratories, a pharmaceutical firm in the US, launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV) in May 2024. These resources are designed to meet the increasing demands of cell and gene therapy (CGT) advancement. The portfolio eases the transition from early-stage research to GMP-grade production, providing a more streamlined process and augmenting the consistency in viral vector manufacturing. This launch aims to tackle a significant hurdle in elevating CGT programs to clinical and commercial readiness.

View the full report here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

How Is the Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Defined and What Are Its Core Parameters?

Adeno-associated virus (AAV) vectors in gene therapy are advanced delivery tools that transport genetic material into cells to treat various genetic disorders. Their primary goal is to enable targeted, long-lasting therapeutic effects by correcting or modifying faulty genes. AAV vectors are valued for their safety, low immunogenicity, and ability to deliver genes to both dividing and non-dividing cells, supporting the development of precise and durable gene therapies that advance personalized medicine and transform the treatment of rare and inherited diseases.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model